Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sevoflurane + nitrous oxide is a combination of two inhaled anesthetic agents commonly used for the induction and maintenance of general anesthesia in both adult and pediatric patients. Sevoflurane is a volatile halogenated ether anesthetic that acts primarily by enhancing inhibitory neurotransmission (notably via GABA(A) and glycine receptors) and inhibiting excitatory synaptic activity (including antagonism at glutamate receptors). Nitrous oxide, also known as "laughing gas," is an inhaled anesthetic with analgesic properties that works mainly as an NMDA receptor antagonist. When used together, these agents provide rapid onset anesthesia with muscle relaxation, amnesia, hypnosis, and analgesia. The combination is widely employed in surgical settings due to its favorable pharmacokinetic profile—sevoflurane offers fast induction/emergence while nitrous oxide augments the depth of anesthesia and reduces the required dose of sevoflurane[1][2][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sevoflurane + nitrous oxide.